Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme

OBJECTIVES: In 2013, the herpes zoster (HZ) immunisation programme was introduced in the UK, recommending vaccination of adults 70 years of age (YOA) with the zoster vaccine live (ZVL), the only vaccine available at the time. The recently approved adjuvanted recombinant zoster vaccine (RZV) has a su...

Descripción completa

Detalles Bibliográficos
Autores principales: van Oorschot, Desirée A M, Hunjan, Manjit, Bracke, Benjamin, Lorenc, Stéphane, Curran, Desmond, Starkie-Camejo, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502027/
https://www.ncbi.nlm.nih.gov/pubmed/31061027
http://dx.doi.org/10.1136/bmjopen-2018-025553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502027/
https://www.ncbi.nlm.nih.gov/pubmed/31061027
http://dx.doi.org/10.1136/bmjopen-2018-025553

Ejemplares similares